Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
PR Newswire —
Raised over $20 million in gross proceeds in 2025 and held $11.9 million in cash and cash equivalents as of December 31, 2025, with a cash runway into the second quarter of 2027 IT-01 Study manuscript of INT230-6 used alone in 64 refractory metastatic cancer patients published in the...